CY2008007I2 - Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου - Google Patents

Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου

Info

Publication number
CY2008007I2
CY2008007I2 CY200800007C CY2008007C CY2008007I2 CY 2008007 I2 CY2008007 I2 CY 2008007I2 CY 200800007 C CY200800007 C CY 200800007C CY 2008007 C CY2008007 C CY 2008007C CY 2008007 I2 CY2008007 I2 CY 2008007I2
Authority
CY
Cyprus
Prior art keywords
dexamethazone
cancer
combination therapy
therapeutic treatment
therapeutic
Prior art date
Application number
CY200800007C
Other languages
English (en)
Other versions
CY2008007I1 (el
Original Assignee
Pharma Mar, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharma Mar, S.A. filed Critical Pharma Mar, S.A.
Publication of CY2008007I1 publication Critical patent/CY2008007I1/el
Publication of CY2008007I2 publication Critical patent/CY2008007I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CY200800007C 1999-05-13 2008-04-07 Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου CY2008007I2 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound
PCT/GB2000/001857 WO2000069441A1 (en) 1999-05-13 2000-05-15 Compositions and uses of et743 for treating cancer

Publications (2)

Publication Number Publication Date
CY2008007I1 CY2008007I1 (el) 2009-11-04
CY2008007I2 true CY2008007I2 (el) 2009-11-04

Family

ID=27546594

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20061101734T CY1105818T1 (el) 1999-05-13 2006-11-30 Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
CY20081100059T CY1107143T1 (el) 1999-05-13 2008-01-16 Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
CY200800007C CY2008007I2 (el) 1999-05-13 2008-04-07 Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
CY20111100545T CY1112753T1 (el) 1999-05-13 2011-06-08 Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20061101734T CY1105818T1 (el) 1999-05-13 2006-11-30 Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
CY20081100059T CY1107143T1 (el) 1999-05-13 2008-01-16 Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100545T CY1112753T1 (el) 1999-05-13 2011-06-08 Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743

Country Status (32)

Country Link
US (1) US8119638B2 (el)
EP (3) EP1702618B1 (el)
JP (2) JP2002544231A (el)
KR (1) KR20020019914A (el)
CN (2) CN100477993C (el)
AR (1) AR028476A1 (el)
AT (3) ATE338552T1 (el)
AU (2) AU777417B2 (el)
BG (1) BG65680B1 (el)
BR (1) BR0010531A (el)
CA (1) CA2373794C (el)
CY (4) CY1105818T1 (el)
CZ (1) CZ301482B6 (el)
DE (4) DE122008000013I1 (el)
DK (3) DK1716853T3 (el)
ES (2) ES2294756T3 (el)
FR (1) FR08C0013I2 (el)
HU (2) HU229866B1 (el)
IL (2) IL146434A0 (el)
LU (1) LU91418I2 (el)
MX (1) MXPA01011562A (el)
MY (1) MY164077A (el)
NL (1) NL300337I2 (el)
NO (2) NO324564B1 (el)
NZ (1) NZ515423A (el)
PL (1) PL198185B1 (el)
PT (3) PT1176964E (el)
SI (3) SI1716853T1 (el)
SK (1) SK287580B6 (el)
TR (1) TR200103819T2 (el)
UA (1) UA74782C2 (el)
WO (1) WO2000069441A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2428160C (en) * 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
HUP0401903A3 (en) * 2001-10-19 2008-07-28 Pharma Mar Improved use of et-743 in cancer thereapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
RS50692B (sr) * 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
MX2007000360A (es) * 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
NZ554765A (en) * 2004-10-26 2010-01-29 Pharma Mar Sa Pegylated Liposomal Doxorubicin In Combination With Ecteinescidin 743
DE602005001833T2 (de) * 2004-10-29 2008-04-17 Pharma Mar S.A., Sociedad Unipersonal Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
JP2009536956A (ja) * 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
MX2018009088A (es) 2016-02-04 2018-09-03 Jiangsu Hengrui Medicine Co Composicion farmaceutica inyectable que incluye trabectedina para uso gastrointestinal externo y metodo para la fabricacion de la misma.
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
EP4041194B1 (en) 2020-04-15 2024-03-13 EVER Valinject GmbH Composition comprising trabectedin and an amino acid
US20230226051A1 (en) 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
WO1987007610A2 (en) * 1986-06-09 1987-12-17 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
JPH09503743A (ja) * 1993-05-14 1997-04-15 デポテック コーポレーション 神経学的疾患の治療方法
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
DE69738935D1 (de) * 1996-11-05 2008-10-02 Childrens Medical Center Zusammensetzungen enthaltend Thalidomide und Dexamethason für die Behandlung von Krebs
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
EP1077698B1 (en) * 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
CA2406080C (en) 2000-04-12 2011-11-29 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
JP2004506430A (ja) 2000-08-11 2004-03-04 シティ・オブ・ホープ Ｓｘｒによるトランス活性化の抗新生物剤ｅｔ−７４３による阻害
CA2428160C (en) 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
EP1372658A2 (en) 2001-03-30 2004-01-02 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
HUP0401903A3 (en) 2001-10-19 2008-07-28 Pharma Mar Improved use of et-743 in cancer thereapy
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
RS50692B (sr) 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
MX2007000360A (es) 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
US20080242670A2 (en) 2004-09-29 2008-10-02 Pharma Mar S.A., Sociedad Unipersonal Anti-Inflammatory Agents
NZ554765A (en) 2004-10-26 2010-01-29 Pharma Mar Sa Pegylated Liposomal Doxorubicin In Combination With Ecteinescidin 743
DE602005001833T2 (de) 2004-10-29 2008-04-17 Pharma Mar S.A., Sociedad Unipersonal Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide
DE602006020335D1 (de) 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
JP2009536956A (ja) 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Also Published As

Publication number Publication date
PT1716853E (pt) 2011-05-12
UA74782C2 (uk) 2006-02-15
DE60036826D1 (de) 2007-11-29
SI1176964T1 (sl) 2007-02-28
PT1176964E (pt) 2007-01-31
CZ20014081A3 (cs) 2002-11-13
HUS1500001I1 (hu) 2016-08-29
CZ301482B6 (cs) 2010-03-17
CA2373794C (en) 2005-10-11
SK287580B6 (sk) 2011-03-04
PT1702618E (pt) 2008-01-11
IL146434A (en) 2008-03-20
SI1716853T1 (sl) 2011-10-28
AU777417B2 (en) 2004-10-14
FR08C0013I2 (fr) 2009-10-30
DE60030554T2 (de) 2007-09-13
BG65680B1 (bg) 2009-06-30
NL300337I1 (nl) 2008-05-01
NL300337I2 (nl) 2008-09-01
JP2002544231A (ja) 2002-12-24
AR028476A1 (es) 2003-05-14
NO324564B1 (no) 2007-11-19
DE60045720D1 (de) 2011-04-21
JP5777562B2 (ja) 2015-09-09
CA2373794A1 (en) 2000-11-23
BR0010531A (pt) 2002-06-04
EP1176964B1 (en) 2006-09-06
US8119638B2 (en) 2012-02-21
PL352931A1 (en) 2003-09-22
LU91418I2 (fr) 2008-05-13
AU4597500A (en) 2000-12-05
US20070275942A1 (en) 2007-11-29
FR08C0013I1 (el) 2008-05-30
CN1679631A (zh) 2005-10-12
SK16442001A3 (sk) 2002-03-05
EP1716853B1 (en) 2011-03-09
MY164077A (en) 2017-11-30
CN100477993C (zh) 2009-04-15
EP1716853B9 (en) 2011-09-28
SI1702618T1 (sl) 2008-02-29
EP1702618A3 (en) 2006-12-27
PL198185B1 (pl) 2008-06-30
EP1716853A3 (en) 2006-11-15
WO2000069441A1 (en) 2000-11-23
BG106171A (en) 2002-06-28
CY1112753T1 (el) 2016-02-10
NO20015516L (no) 2002-01-11
CY2008007I1 (el) 2009-11-04
AU2005200180B2 (en) 2007-12-13
ATE375795T1 (de) 2007-11-15
CN1360503A (zh) 2002-07-24
DE60030554T8 (de) 2008-01-10
MXPA01011562A (es) 2002-07-30
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19
DK1702618T3 (da) 2008-02-25
ES2272279T3 (es) 2007-05-01
CY1105818T1 (el) 2011-02-02
EP1176964B8 (en) 2007-10-10
HUP0201187A2 (en) 2002-09-28
NO2008005I1 (no) 2008-06-09
EP1176964A1 (en) 2002-02-06
HU229866B1 (en) 2014-10-28
EP1702618B1 (en) 2007-10-17
DK1716853T3 (da) 2011-06-27
EP1716853A2 (en) 2006-11-02
NO20015516D0 (no) 2001-11-12
JP2012149095A (ja) 2012-08-09
LU91418I9 (el) 2019-01-02
NO2008005I2 (el) 2010-09-27
AU2005200180B9 (en) 2008-05-29
HUP0201187A3 (en) 2002-11-28
ES2294756T3 (es) 2008-04-01
ATE338552T1 (de) 2006-09-15
DK1176964T3 (da) 2007-01-15
ATE500830T1 (de) 2011-03-15
DE122008000013I1 (de) 2008-08-07
NZ515423A (en) 2004-04-30
CY1107143T1 (el) 2010-07-28
IL146434A0 (en) 2002-07-25
TR200103819T2 (tr) 2002-04-22
KR20020019914A (ko) 2002-03-13
DE60036826T2 (de) 2008-08-28
EP1702618A2 (en) 2006-09-20

Similar Documents

Publication Publication Date Title
CY2008007I1 (el) Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
CY2015044I1 (el) Θεραπευτικη αγωγη ογκων του μαστου με παραγωγο ραπαμυκινης σε συνδυασμο με εξεμεστανη
EP1311262A4 (en) COMBINED TREATMENT AGAINST CANCER
IL164599A0 (en) Combination therapy for the treatment of cancer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EE200100370A (et) Teraapias kasutatavad spirofuropüridiinide uued aralküülamiinid
DE60138611D1 (de) Synergistische kombinationstherapie zur krebsbehandlung
DE59913730D1 (de) Herztherapiegerät
DE69525347D1 (de) Krebsbehandlung mittels humanen choriongonadotropin
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
IL158329A0 (en) Antiangiogenic combination therapy for the treatment of cancer
HUP0500424A3 (en) Combination therapy for the treatment of cancer
NO20014725L (no) Forbedret kreftbehandling med temozolomid
HUP0300339A3 (en) Use of fulvestrant in the treatment of resistant breast cancer
EE200100623A (et) Melatoniini terapeutiline kasutamine
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
FI973185A (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
NO953349L (no) Kombinasjonsterapi av human cancer med cisplatin/tamoxifen
NO20014228D0 (no) Radioaktiv cisplatin i behandling av cancer
DE29801793U1 (de) Therapie- und Behandlungsgerät
GB0130733D0 (en) Therapeutic compounds and their use in therapy
SI1272195T1 (sl) Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk
GB9901505D0 (en) Therapeutic treatment
GB9918785D0 (en) Therapeutic treatment
GB9910197D0 (en) Multivalent agents for use in the treatment of mitochondrial diseases